Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Apr;99(4):1236-44.
doi: 10.1210/jc.2013-3665. Epub 2014 Jan 13.

Effects of testosterone and growth hormone on the structural and mechanical properties of bone by micro-MRI in the distal tibia of men with hypopituitarism

Affiliations
Randomized Controlled Trial

Effects of testosterone and growth hormone on the structural and mechanical properties of bone by micro-MRI in the distal tibia of men with hypopituitarism

Mona Al Mukaddam et al. J Clin Endocrinol Metab. 2014 Apr.

Abstract

Context: Severe deficiencies of testosterone (T) and GH are associated with low bone mineral density (BMD) and increased fracture risk. Replacement of T in hypogonadal men improves several bone parameters. Replacement of GH in GH-deficient men improves BMD.

Objective: Our objective was to determine whether T and GH treatment together improves the structural and mechanical parameters of bone more than T alone in men with hypopituitarism.

Design and subjects: This randomized, prospective, 2-year study included 32 men with severe deficiencies of T and GH due to panhypopituitarism.

Intervention: Subjects were randomized to receive T alone (n = 15) or T and GH (n = 17) for 2 years.

Main outcome measures: We evaluated magnetic resonance microimaging-derived structural (bone volume fraction [BVF] and trabecular thickness) and mechanical (axial stiffness [AS], a measure of bone strength) properties of the distal tibia at baseline and after 1 and 2 years of treatment.

Results: Treatment with T and GH did not affect BVF, thickness, or AS differently from T alone. T treatment in all subjects for 2 years increased trabecular BVF by 9.6% (P < .0001), trabecular thickness by 2.6% (P < .001), and trabecular AS by 9.8% (P < .001). In contrast, testosterone treatment in all subjects significantly increased cortical thickness by 2.4% (P < .01) but decreased cortical BVF by -4.7% (P < .01) and cortical AS by -6.9% (P < .01).

Conclusion: Combined T and GH treatment of men with hypopituitarism for 2 years did not improve the measured structural or mechanical parameters of the distal tibia more than T alone. However, testosterone significantly increased the structural and mechanical properties of trabecular bone but decreased most of these properties of cortical bone, illustrating the potential importance of assessing trabecular and cortical bone separately in future studies of the effect of testosterone on bone.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Separation of cortical bone from trabecular bone. BVF maps were derived from midaxial FLASE μMRI images obtained from the right tibial metaphysis. BVF represents fractional occupancy of bone linearly scaled between 0% (pure marrow, shown as black) and 100% (pure bone, shown as white) in each voxel. A single operator, starting with whole bone (WB), delineated the endosteal and periosteal boundaries of cortical bone to separate cortical bone (CB) from surrounding soft tissue and trabecular bone (TB) from the cortex.
Figure 2.
Figure 2.
Serum concentrations of testosterone (A), estradiol (B), and IGF-1 (C) at baseline and after 3, 6, 12, 18, and 24 months of treatment with testosterone (n = 15) or testosterone and growth hormone (n = 17).
Figure 3.
Figure 3.
Contrast between the effects of testosterone and GH on trabecular bone structure (A and B) and their effects on cortical bone structure (C and D). Illustrated are the percent changes in trabecular BVF (A), Tb.Th (B), cortical BVF (C), and Ct.Th (D) of the distal tibia from baseline to 12 and 24 months after treatment with testosterone (n = 15) and testosterone and GH (n = 17) and in all subjects (n = 32). There was no significant difference between the 2 treatment groups at any time point. *, P < .01; **, P < .001; ***, P < .0001 compared with baseline; †, P < .05, 24 months compared with 12 months in all subjects.
Figure 4.
Figure 4.
Comparison of the effects of testosterone and GH on trabecular bone strength (A), cortical bone strength (B), and whole bone strength (C). Illustrated are the percent changes in AS of the distal tibia from baseline to 12 and 24 months after treatment with testosterone (n = 15) and testosterone and GH (n = 17) and in all subjects (n = 32). AS was determined by μMRI-based FEA of trabecular bone (A), cortical bone (B), and whole bone (C). There was no significant difference between the 2 treatment groups at any time point. *, P < .01; **, P < .001, compared with baseline; †, P < .05; ††, P < .001, 24 months compared with 12 months in all subjects.

References

    1. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005;90:6410–6417 - PubMed
    1. Stepán JJ, Lachman M, Zverina J, Pacovský V, Baylink DJ. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab. 1989;69:523–527 - PubMed
    1. Wadhwa VK, Weston R, Mistry R, Parr NJ. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int. 2009;104:800–805 - PubMed
    1. Hamilton EJ, Ghasem-Zadeh A, Gianatti E, et al. Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy. J Clin Endocrinol Metab. 2010;95:E456–E463 - PubMed
    1. Benito M, Gomberg B, Wehrli FW, et al. Deterioration of trabecular architecture in hypogonadal men. J Clin Endocrinol Metab. 2003;88:1497–1502 - PubMed

Publication types

MeSH terms